Hae-Ji Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hae-Ji Kang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Fu-Shi Quan
Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Research Institute (CRI), Kyung Hee University, Seoul 02447, Republic of Korea
5 shared publications - Keon-Woong Yoon
Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea
4 shared publications - Ki Back Chu
Department of Parasitology, College of Medicine, Inje University, Busan 47392, Republic of Korea
4 shared publications - Eun-Kyung Moon
Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul 02447, Korea
3 shared publications - Gi-Deok Eom
Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea
3 shared publications - Jie Mao
Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 19 November 2025
- Published by Korean Society for Parasitology in Parasites, Hosts and Diseases
- Vol. 63 (4) , 340-348
Vaccinia virus expressing MIC8 and AMA1 provides protection against Toxoplasma gondii ME49 infection
Toxoplasma gondii is an intracellular protozoan parasite capable of causing chronic infection by forming persistent cysts in the brain. Despite its global burden, no approved vaccine exists. Virus-like particle vaccines expressing microneme protein 8 (MIC8) or apical membrane antigen 1 (AMA1) of T. gondii have previously shown efficacy. In this study, we generated recombinant vaccinia viruses (rVVs) expressing MIC8 and AMA1 and evaluated their efficacy against T. gondii ME49 infection. BALB/c mice were intramuscularly immunized with a combination of MIC8 and AMA1 rVVs and challenged orally with T. gondii ME49. Immunization with MIC8+AMA1 rVVs produced a significant increase in T. gondii-specific IgG. Splenocyte analysis revealed robust activation of CD4+ and CD8+ T cells, as well as expansion of memory B cells. The immunized group exhibited an 89.6% reduction in brain cyst count, with significantly improved survival compared to the control group. These findings demonstrate that combining the antigens MIC8 and AMA1 using a vaccinia virus platform can effectively promote both humoral and cellular immunity, supporting its potential as a vaccine strategy against T. gondii ME49.
- 19 November 2025
- Published by Korean Society for Parasitology in Parasites, Hosts and Diseases
- Vol. 63 (4) , 340-348
Open AccessVaccinia virus expressing MIC8 and AMA1 provides protection against Toxoplasma gondii ME49 infection
Toxoplasma gondii is an intracellular protozoan parasite capable of causing chronic infection by forming persistent cysts in the brain. Despite its global burden, no approved vaccine exists. Virus-like particle vaccines expressing microneme protein 8 (MIC8) or apical membrane antigen 1 (AMA1) of T. gondii have previously shown efficacy. In this study, we generated recombinant vaccinia viruses (rVVs) expressing MIC8 and AMA1 and evaluated their efficacy against T. gondii ME49 infection. BALB/c mice were intramuscularly immunized with a combination of MIC8 and AMA1 rVVs and challenged orally with T. gondii ME49. Immunization with MIC8+AMA1 rVVs produced a significant increase in T. gondii-specific IgG. Splenocyte analysis revealed robust activation of CD4+ and CD8+ T cells, as well as expansion of memory B cells. The immunized group exhibited an 89.6% reduction in brain cyst count, with significantly improved survival compared to the control group. These findings demonstrate that combining the antigens MIC8 and AMA1 using a vaccinia virus platform can effectively promote both humoral and cellular immunity, supporting its potential as a vaccine strategy against T. gondii ME49.
- 25 September 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (29) , 2437-2446
Heterologous immunization targeting the CST1 antigen confers better protection than ROP18 in mice
Aim: To evaluate the protective efficacy induced by heterologous immunization with recombinant baculoviruses or virus-like particles targeting the CST1 and ROP18 antigens of Toxoplasma gondii.Materials & methods: Recombinant baculovirus and virus-like particle vaccines expressing T. gondii CST1 or ROP18 antigens were developed to evaluate protective immunity in mice upon challenge infection with 450 Toxoplasma gondii (ME49).Results: Immunization with CST1 or ROP18 vaccines induced similar levels of T. gondii-specific IgG and IgA responses. Compared with ROP 18, CST1 vaccine showed better antibody-secreting cell response, germinal center B cell activation, and significantly reduced brain cyst burden and body weight loss.Conclusion: Our findings suggest that CST1 heterologous immunization elicited better protection than ROP18, providing important insight into improving the toxoplasmosis vaccine design strategy.
- 25 September 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (29) , 2437-2446
Heterologous immunization targeting the CST1 antigen confers better protection than ROP18 in mice
Aim: To evaluate the protective efficacy induced by heterologous immunization with recombinant baculoviruses or virus-like particles targeting the CST1 and ROP18 antigens of Toxoplasma gondii.Materials & methods: Recombinant baculovirus and virus-like particle vaccines expressing T. gondii CST1 or ROP18 antigens were developed to evaluate protective immunity in mice upon challenge infection with 450 Toxoplasma gondii (ME49).Results: Immunization with CST1 or ROP18 vaccines induced similar levels of T. gondii-specific IgG and IgA responses. Compared with ROP 18, CST1 vaccine showed better antibody-secreting cell response, germinal center B cell activation, and significantly reduced brain cyst burden and body weight loss.Conclusion: Our findings suggest that CST1 heterologous immunization elicited better protection than ROP18, providing important insight into improving the toxoplasmosis vaccine design strategy.
- Open Access
- 27 May 2024
- Published by Korean Society for Parasitology in Parasites, Hosts and Diseases
- Vol. 62 (2) , 193-204
Virus-like particles expressing microneme-associated antigen of Plasmodium berghei confer better protection than those expressing apical membrane antigen 1
Malaria is a global disease affecting a large portion of the world’s population. Although vaccines have recently become available, their efficacies are suboptimal. We generated virus-like particles (VLPs) that expressed either apical membrane antigen 1 (AMA1) or microneme-associated antigen (MIC) of Plasmodium berghei and compared their efficacy in BALB/c mice. We found that immune sera acquired from AMA1 VLP- or MIC VLP-immunized mice specifically interacted with the antigen of choice and the whole P. berghei lysate antigen, indicating that the antibodies were highly parasite-specific. Both VLP vaccines significantly enhanced germinal center B cell frequencies in the inguinal lymph nodes of mice compared with the control, but only the mice that received MIC VLPs showed significantly enhanced CD4+ T cell responses in the blood following P. berghei challenge infection. AMA1 and MIC VLPs significantly suppressed TNF-α and interleukin-10 production but had a negligible effect on interferon-γ. Both VLPs prevented excessive parasitemia buildup in immunized mice, although parasite burden reduction induced by MIC VLPs was slightly more effective than that induced by AMA1. Both VLPs were equally effective at preventing body weight loss. Our findings demonstrated that the MIC VLP was an effective inducer of protection against murine experimental malaria and should be the focus of further development.
- 27 May 2024
- Published by Korean Society for Parasitology in Parasites, Hosts and Diseases
- Vol. 62 (2) , 193-204
Open AccessVirus-like particles expressing microneme-associated antigen of Plasmodium berghei confer better protection than those expressing apical membrane antigen 1
Malaria is a global disease affecting a large portion of the world’s population. Although vaccines have recently become available, their efficacies are suboptimal. We generated virus-like particles (VLPs) that expressed either apical membrane antigen 1 (AMA1) or microneme-associated antigen (MIC) of Plasmodium berghei and compared their efficacy in BALB/c mice. We found that immune sera acquired from AMA1 VLP- or MIC VLP-immunized mice specifically interacted with the antigen of choice and the whole P. berghei lysate antigen, indicating that the antibodies were highly parasite-specific. Both VLP vaccines significantly enhanced germinal center B cell frequencies in the inguinal lymph nodes of mice compared with the control, but only the mice that received MIC VLPs showed significantly enhanced CD4+ T cell responses in the blood following P. berghei challenge infection. AMA1 and MIC VLPs significantly suppressed TNF-α and interleukin-10 production but had a negligible effect on interferon-γ. Both VLPs prevented excessive parasitemia buildup in immunized mice, although parasite burden reduction induced by MIC VLPs was slightly more effective than that induced by AMA1. Both VLPs were equally effective at preventing body weight loss. Our findings demonstrated that the MIC VLP was an effective inducer of protection against murine experimental malaria and should be the focus of further development.
- 23 February 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (9) , 741-754
Crossprotection Induced by Virus-Like Particles Containing Influenza Dual-Hemagglutinin and M2 Ectodomain
Aims: To develop an effective universal vaccine against antigenically different influenza viruses. Materials & methods: We generated influenza virus-like particles (VLPs) expressing the H1 and H3 a... Graphical abstract
- 23 February 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (9) , 741-754
Crossprotection Induced by Virus-Like Particles Containing Influenza Dual-Hemagglutinin and M2 Ectodomain
Aims: To develop an effective universal vaccine against antigenically different influenza viruses. Materials & methods: We generated influenza virus-like particles (VLPs) expressing the H1 and H3 a... Graphical abstract
- Open Access
- 28 November 2023
- Published by Korean Society for Parasitology in Parasites, Hosts and Diseases
- Vol. 61 (4) , 418-427
The detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques
Toxoplasma gondii infections are primarily diagnosed by serological assays, whereas molecular and fluorescence-based techniques are garnering attention for their high sensitivity in detecting these infections. Nevertheless, each detection method has its limitations. The toxoplasmosis detection capabilities of most of the currently available methods have not been evaluated under identical experimental conditions. This study aimed to assess the diagnostic potential of enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC), and immunofluorescence (IF) in BALB/c mice experimentally infected with various doses of T. gondii ME49. The detection of toxoplasmosis from sera and brain tissues was markedly enhanced in mice subjected to high infection doses (200 and 300 cysts) compared to those subjected to lower doses (10 and 50 cysts) for all the detection methods. Additionally, increased B1 gene expression levels and cyst sizes were observed in the brain tissues of the mice. Importantly, IHC, IF, and ELISA, but not RT-PCR, successfully detected T. gondii infections at the lowest infection dose (10 cysts) in the brain. These findings may prove beneficial while designing experimental methodologies for detecting T. gondii infections in mice.
- 28 November 2023
- Published by Korean Society for Parasitology in Parasites, Hosts and Diseases
- Vol. 61 (4) , 418-427
Open AccessThe detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques
Toxoplasma gondii infections are primarily diagnosed by serological assays, whereas molecular and fluorescence-based techniques are garnering attention for their high sensitivity in detecting these infections. Nevertheless, each detection method has its limitations. The toxoplasmosis detection capabilities of most of the currently available methods have not been evaluated under identical experimental conditions. This study aimed to assess the diagnostic potential of enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC), and immunofluorescence (IF) in BALB/c mice experimentally infected with various doses of T. gondii ME49. The detection of toxoplasmosis from sera and brain tissues was markedly enhanced in mice subjected to high infection doses (200 and 300 cysts) compared to those subjected to lower doses (10 and 50 cysts) for all the detection methods. Additionally, increased B1 gene expression levels and cyst sizes were observed in the brain tissues of the mice. Importantly, IHC, IF, and ELISA, but not RT-PCR, successfully detected T. gondii infections at the lowest infection dose (10 cysts) in the brain. These findings may prove beneficial while designing experimental methodologies for detecting T. gondii infections in mice.